{"id":44828,"date":"2022-06-08T07:01:25","date_gmt":"2022-06-08T05:01:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/university-of-manchester-adds-carterras-lsa-instrument-for-high-throughput-antibody-screening-and-characterization\/"},"modified":"2022-06-08T07:01:25","modified_gmt":"2022-06-08T05:01:25","slug":"university-of-manchester-adds-carterras-lsa-instrument-for-high-throughput-antibody-screening-and-characterization","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/university-of-manchester-adds-carterras-lsa-instrument-for-high-throughput-antibody-screening-and-characterization\/","title":{"rendered":"University of Manchester Adds Carterra\u2019s LSA\u00ae Instrument for High-Throughput Antibody Screening and Characterization"},"content":{"rendered":"
\n

\nWellcome Centre for Cell-Matrix Research is funding a nanobody screening project leveraging Carterra\u2019s platform<\/i>\n<\/p>\n

MANCHESTER, England & SALT LAKE CITY–(BUSINESS WIRE)–The University of Manchester, United Kingdom, and Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, announced today that the University of Manchester has added Carterra\u2019s LSA instrument to its Biomolecular Analysis Core Facility (BACF) within the Faculty of Biology, Medicine and Health (FBMH).\n<\/p>\n

\nThe BACF was created in 2005 to facilitate the characterization of biomolecules and their molecular interactions. The facility, which comprises a suite of biophysical instruments, supports University research through access to its resident technologies, project-specific advice, sample analysis, instrument training, as well as data interpretation and reporting. The BACF also supports research at other higher education institutions in the UK as well as in the pharmaceutical industry.\n<\/p>\n

\n\u201cOur job in the BACF is to provide our university\u2019s scientists with the world\u2019s best and most advanced technologies for molecular interaction analysis\u2014we have certainly fulfilled our remit by adding Carterra\u2019s LSA to our stable of technologies,\u201d says Tony Day, a Professor of Biochemistry within FBMH and Academic Lead for the BACF.\n<\/p>\n

\nThe Wellcome Trust, through the University\u2019s Wellcome Centre for Cell-Matrix Research, is funding a project to generate nanobodies\u2014antibodies with a single variable domain, also known as VHH antibodies. The aim of this project is to assemble an immunoassay toolbox for the study of matrix biology including the analysis of tissues from fibrotic diseases that will help underpin the development of new diagnostic and therapeutic targets.\n<\/p>\n

\nThe high-throughput capabilities of Carterra\u2019s LSA, measuring hundreds of binding events in parallel and providing high-resolution epitope binning, will remove a bottleneck in the nanobody production process allowing experiments that would previously take many days to be performed in just a few hours. The LSA will allow university researchers to cast a wider net and screen more nanobodies per target, thereby increasing the likelihood of identifying the ideal hit.\n<\/p>\n

\n\u201cWe can\u2019t wait to use the LSA for our development and characterization of nanobodies for which Carterra\u2019s instrument is perfectly suited,\u201d commented Dr. Tom Jowitt, the Manager of the BACF.\n<\/p>\n

\nCarterra launched the LSA antibody discovery and characterization platform in 2018 and has quickly made it the standard in 17 of the 20 largest pharmaceutical companies, biotechs, CROs, and government labs. The speed at which antibodies can now be identified and characterized as potential drugs by Carterra\u2019s LSA has improved on traditional methods by generating results 100 times faster while using 99% less sample. Sensitivity for finding the rarest of antibodies in a complex matrix is also now best-in-class.\n<\/p>\n

\nOther highlights from Carterra\u2019s success with the LSA platform include the following:\n<\/p>\n